Stockscreener 앱 받기
0.5308
2.82%
-0.0154
시간 외 거래:
.53
-0.0008
-0.15%
전일 마감가:
$0.5462
열려 있는:
$0.538
하루 거래량:
40,356
Relative Volume:
0.33
시가총액:
$13.90M
수익:
-
순이익/손실:
$-26.56M
주가수익비율:
-0.8166
EPS:
-0.65
순현금흐름:
$-22.29M
1주 성능:
-2.91%
1개월 성능:
-2.77%
6개월 성능:
+7.93%
1년 성능:
-85.46%
1일 변동 폭
$0.52
$0.5473
1주일 범위
$0.5013
$0.58
52주 변동 폭
$0.477
$4.90
BiomX Inc Stock (PHGE) Company Profile
명칭
BiomX Inc
전화
972 7 23942377
주소
7 Pinhas Sapir Street, 2nd Floor, Ness Ziona
PHGE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PHGE
BiomX Inc
|
0.5308 | 13.65M | 0 | -26.56M | -22.29M | -0.65 |
|
ONC
Beigene Ltd Adr
|
236.49 | 23.78B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.32 | 108.15B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.24 | 43.44M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
604.62 | 61.69B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.09 | 5.72B | 0 | -153.72M | -103.81M | -2.00 |
BiomX Inc Stock (PHGE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-04-15 | 개시 | Ladenburg Thalmann | Buy |
BiomX Inc 주식(PHGE)의 최신 뉴스
BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference | PHGE Stock News - GuruFocus
BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference - GlobeNewswire
BiomX Inc. (AMEX:PHGE) Q1 2025 Earnings Call Transcript - MSN
HC Wainwright Issues Pessimistic Forecast for BiomX (NYSEAMERICAN:PHGE) Stock Price - Defense World
BiomX Inc. Earnings Call: Optimism and Progress - TipRanks
PHGE: HC Wainwright & Co. Maintains Buy Rating, Lowers Price Tar - GuruFocus
BiomX (PHGE) Price Target Reduced by Analyst Yet Buy Rating Maintained | PHGE Stock News - GuruFocus
BiomX Inc (PHGE) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience - Yahoo Finance
BiomX Inc. Reports Q1 2025 Progress and Financials - TipRanks
BiomX Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
BiomX Inc. SEC 10-Q Report - TradingView
BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates - TradingView
BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates | PHGE Stock News - GuruFocus
BiomX Breakthrough: Phase 2 Trial Reveals 40% Superior Efficacy in Fighting Antibiotic-Resistant Infections - Stock Titan
BiomX (PHGE) to Release Quarterly Earnings on Thursday - Defense World
BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025 - GlobeNewswire
BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025 | PHGE Stock News - GuruFocus
BiomX Inc. to Host Conference Call for First Quarter 2025 Financial Results and Business Updates - Nasdaq
JPMorgan Chase & Co. Invests $314,000 in BiomX Inc. (NYSEMKT:PHGE) - Defense World
Short Interest in BiomX Inc. (NYSEAMERICAN:PHGE) Decreases By 48.2% - Defense World
BiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
HC Wainwright Reiterates “Buy” Rating for BiomX (NYSEMKT:PHGE) - Defense World
Q1 Earnings Estimate for BiomX Issued By HC Wainwright - Defense World
What is HC Wainwright’s Estimate for BiomX FY2025 Earnings? - Defense World
What is HC Wainwright’s Forecast for BiomX Q1 Earnings? - Defense World
HC Wainwright Issues Positive Forecast for BiomX (NYSEAMERICAN:PHGE) Stock Price - Defense World
Earnings call transcript: Biomx Q1 2025 sees potential breakthrough in phage therapy By Investing.com - Investing.com South Africa
Earnings call transcript: Biomx Q1 2025 sees potential breakthrough in phage therapy - Investing.com India
Biomx stock plunges to 52-week low, hits $0.48 - Investing.com
Biomx stock plunges to 52-week low, hits $0.48 By Investing.com - Investing.com India
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure - GlobeNewswire
BiomX stock target soars to $21 on Phase 2 trial success - Investing.com India
BiomX Announces Positive Phase 2 Trial Results - TipRanks
BiomX reports progress in diabetic ulcer treatment By Investing.com - Investing.com Australia
BiomX reports progress in diabetic ulcer treatment - Investing.com India
BiomX Announces Positive Topline Results From Phase 2 Trial Evaluating Bx211 For The Treatment Of Diabetic Foot Osteomyelitis (DFO) - MarketScreener
BiomX Announces Positive Topline Results from Phase 2 Trial - GlobeNewswire
Major Clinical Success: BiomX's New Drug Shows Promise in Preventing Diabetic Amputations - Stock Titan
Phage Therapy Market Know the Scope and Trends - openPR
BiomX (PHGE) Expected to Announce Earnings on Wednesday - Defense World
BiomX Inc Reports Q4 2024 EPS of -$2.56, Revenue at $0.00 Millio - GuruFocus
BiomX Inc. Secures $12 Million in Financing to Advance Clinical Trials for BX004 and BX211 - Nasdaq
BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates - GlobeNewswire
Earnings Scheduled For March 25, 2025 - Benzinga
BiomX Inc (PHGE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.52%
1.15%
자본화:
|
볼륨(24시간):